Gerilimzumab (GB224) is a humanized monoclonal antibody inhibitor targeting interleukin-6 (IL-6). It is being investigated for potential use in autoimmune disease research, such as rheumatoid arthritis.
Target:
Interleukin
* VAT and and shipping costs not included. Errors and price changes excepted